OTCMKTS:IMLFF InMed Pharmaceuticals (IMLFF) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free IMLFF Stock Alerts $0.23 -0.02 (-8.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.23▼$0.2550-Day Range$0.27▼$0.4452-Week Range$3.04▼$10.63Volume475,401 shsAverage Volume11,369 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get InMed Pharmaceuticals alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About InMed Pharmaceuticals Stock (OTCMKTS:IMLFF)InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, it works on IND-enabling pharmacology and preclinical toxicology studies. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.Read More IMLFF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMLFF Stock News HeadlinesDecember 11, 2023 | benzinga.comInMed's (NASDAQ: INM) Latest Research Demonstrates Potential In Treating Alzheimer's With A Rare Cannabinoid AnalogOctober 18, 2023 | benzinga.comInMed Pharmaceuticals, A Cannabinoid-Focused Company, Sponsored Benzinga's Cannabis Capital ConferenceApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.May 16, 2023 | marketwatch.comCannabisNewsBreaks - InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q3 2023 Financial Results, Provides Business UpdateMay 16, 2023 | msn.comInMed Pharmaceuticals Stock Trading Higher On Q3 Sales Growth Of 234%, Here Is What You Need To KnowMarch 21, 2023 | benzinga.comInMed Pharmaceuticals Stock (NASDAQ:INM), Short Interest ReportJanuary 21, 2023 | seekingalpha.comINM InMed Pharmaceuticals Inc.January 10, 2023 | technews.tmcnet.comInMed Provides Business Update and Milestones for 2023April 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.November 22, 2022 | msn.comInMed Pharmaceuticals Secures $6M Via Private PlacementSeptember 23, 2022 | benzinga.comInMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business UpdateSeptember 13, 2022 | yahoo.comInMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to MarketSeptember 9, 2022 | finance.yahoo.comInMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to MarketAugust 24, 2022 | finanznachrichten.deInMed Pharmaceuticals Inc.: InMed Announces Share Consolidation to Meet Nasdaq Listing CriteriaAugust 23, 2022 | finance.yahoo.comInMed Announces Share Consolidation to Meet Nasdaq Listing CriteriaJune 15, 2022 | apnews.comInMed Pharmaceuticals Closes $5M Direct, Private Placement OfferingsJune 6, 2022 | finance.yahoo.comInMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq RulesJune 1, 2022 | apnews.comInMed Pharmaceuticals (INM): Health and Wellness Product LaunchesNovember 10, 2021 | nasdaq.comInMed Pharmaceuticals Inc. (INM) Reports Q1 Loss, Lags Revenue EstimatesOctober 27, 2021 | benzinga.comDeFi Will End Poorly Without Investor Protections, Gary Gensler SaysSeptember 13, 2021 | benzinga.comInMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare CannabinoidsSeptember 13, 2021 | benzinga.comInMed Pharmaceuticals Inc. Enters Agreement For 'Transformative' Acquisition Of Leading Manufacturer Of Rare CannabinoidsSeptember 7, 2021 | benzinga.comWhere Do Blunts Come From? Who Was The First To Smoke One? Snoop Dogg Weighs InSeptember 6, 2021 | benzinga.comWhat You Need To Know About CBD HashSeptember 4, 2021 | benzinga.comLEGAL: New, Stunning Web Series Looks Into The First Country To Legalize Cannabis And The People Thriving Thanks To ItSeptember 2, 2021 | benzinga.comTerpene Producer Eybna Teams Up With Cannabis Brands Spherex And Orchid EssentialsAugust 26, 2021 | benzinga.comCan Ketamine Be Used To Treat Gambling Addiction? Awakn Life Sciences Wants To Find OutSee More Headlines Receive IMLFF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:IMLFF CUSIPN/A CIKN/A Webwww.inmedpharma.com Phone(604) 669-7207FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Eric A. Adams (Age 56)Pres, CEO & Director Mr. Bruce S. Colwill C.A. (Age 55)CPA, CA, CFO & Corp. Sec. Ms. Alexandra D. J. Mancini (Age 67)Sr. VP of Clinical & Regulatory Affairs Dr. Eric Chih-Hsien Hsu (Age 50)Sr. VP of Preclinical R&D Mr. Michael Woudenberg P.Eng. (Age 53)VP of Chemistry, Manufacturing & Controls Dr. Sazzad HossainCo-FounderMr. Brendan PayneDirector of Investor RelationsMr. Richard HoyVP of Sales & MarketingDr. Ado MuhammadSr. Consultant of Medical AffairsMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors IMLFF Stock Analysis - Frequently Asked Questions How have IMLFF shares performed in 2024? InMed Pharmaceuticals' stock was trading at $0.4160 on January 1st, 2024. Since then, IMLFF shares have decreased by 44.7% and is now trading at $0.23. View the best growth stocks for 2024 here. How do I buy shares of InMed Pharmaceuticals? Shares of IMLFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IMLFF) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsMan Who Predicted 2008: “This Will be Worse.”AltimetryYou Won't Believe Who Bezos is Working With to Fight Alzheimer'sBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
